Lea Rossi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lea Rossi has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Domenico Ferraioli
Centre Leon Berard and Claude Bernard University, Department of Surgical Oncology, Lyon, France
3 shared publications - Enora Laas
Institut Curie 5 Department of Breast, Gynecological and Reconstructive Surgery Université de Paris Cité, Paris and Saint-Cloud, France
3 shared publications - Cécile Loaec
Institut de Cancérologie de l'Ouest, Saint Herblain, France
2 shared publications - Eric Lambaudie
Department of Surgical Oncology, Institut Paoli Calmettes, Marseille, France
2 shared publications Fabrice Narducci
Department of Surgical Oncology, Centre Oscar Lambret, Lille, France
2 shared publications- Frédéric Marchal
Département de Chirurgie, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France
2 shared publications
Latest Publications
- 25 March 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (6) , 111768
Advanced high-grade serous ovarian cancer treated with intensive cytoreductive surgery and chemotherapy: prognostic impact of lymph node involvement: analysis of the French national ESME-Unicancer database
- 25 March 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (6) , 111768
Advanced high-grade serous ovarian cancer treated with intensive cytoreductive surgery and chemotherapy: prognostic impact of lymph node involvement: analysis of the French national ESME-Unicancer database
- Open Access
- 11 December 2025
- Published by Elsevier in Clinical Surgical Oncology
- Vol. 4 (4)
Metastatic sites and surgical management in stage IV ovarian cancer: Is there a place for debulking surgery in FIGO stage IVB patients? A retrospective study from the ESME national cohort
- 11 December 2025
- Published by Elsevier in Clinical Surgical Oncology
- Vol. 4 (4)
Open AccessMetastatic sites and surgical management in stage IV ovarian cancer: Is there a place for debulking surgery in FIGO stage IVB patients? A retrospective study from the ESME national cohort
- 20 June 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (9) , 106963
Do surgeons overestimate diaphragmatic peritoneal disease in interval debulking surgery of ovarian cancer?
- 20 June 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (9) , 106963
Do surgeons overestimate diaphragmatic peritoneal disease in interval debulking surgery of ovarian cancer?
- 24 February 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (2) , e79
Teleconsultation after outpatient total mastectomy
- 24 February 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (2) , e79
Teleconsultation after outpatient total mastectomy
- Open Access
Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)
Most patients with malignant ovarian germ cell tumors (MOGTCs) have a very good prognosis and chemotherapy provides curative treatment; however, patients with yolk sac tumors (OYSTs) have a significantly worse prognosis. OYSTs are rare tumors and promising results are expected with the use of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens. We initiated a project in collaboration with EORTC SPECTA, to explore the molecular characteristics of OYSTs. The pilot project used retrospective samples from ten OYST relapsed and disease-free patients. Each patient had a molecular analysis performed with FoundationOne CDx describing the following variables according to the Foundation Medicine Incorporation (FMI): alteration type (SNV, deletion), actionable gene alteration, therapies approved in EU (for patient’s tumor type and other tumor types), tumor mutational burden (TMB), and microsatellite instability (MSI) status. A total of 10 patients with OYST diagnosed between 2007 and 2017 had a molecular analysis. A molecular alteration was identified in four patients (40%). A subset of three patients (33.3% of all patients) harbored targetable oncogenic mutations in KRAS, KIT, ARID1A. Two patients at relapse harbored a targetable mutation. This retrospective study identifies clinically relevant molecular alterations for all relapsed patients with molecular analysis. Dedicated studies are needed to demonstrate the efficacy of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens and to explore the potential relationship of a molecular alteration and patient outcome.
Open AccessMolecular Characterization of Ovarian Yolk Sac Tumor (OYST)
Most patients with malignant ovarian germ cell tumors (MOGTCs) have a very good prognosis and chemotherapy provides curative treatment; however, patients with yolk sac tumors (OYSTs) have a significantly worse prognosis. OYSTs are rare tumors and promising results are expected with the use of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens. We initiated a project in collaboration with EORTC SPECTA, to explore the molecular characteristics of OYSTs. The pilot project used retrospective samples from ten OYST relapsed and disease-free patients. Each patient had a molecular analysis performed with FoundationOne CDx describing the following variables according to the Foundation Medicine Incorporation (FMI): alteration type (SNV, deletion), actionable gene alteration, therapies approved in EU (for patient’s tumor type and other tumor types), tumor mutational burden (TMB), and microsatellite instability (MSI) status. A total of 10 patients with OYST diagnosed between 2007 and 2017 had a molecular analysis. A molecular alteration was identified in four patients (40%). A subset of three patients (33.3% of all patients) harbored targetable oncogenic mutations in KRAS, KIT, ARID1A. Two patients at relapse harbored a targetable mutation. This retrospective study identifies clinically relevant molecular alterations for all relapsed patients with molecular analysis. Dedicated studies are needed to demonstrate the efficacy of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens and to explore the potential relationship of a molecular alteration and patient outcome.
- 1 December 2017
- Published by Elsevier in Bulletin du Cancer
- Vol. 104 (12) , 1013-1021
Syndrome de Lynch et cancer de l’endomètre
- 1 December 2017
- Published by Elsevier in Bulletin du Cancer
- Vol. 104 (12) , 1013-1021
Syndrome de Lynch et cancer de l’endomètre